567 related articles for article (PubMed ID: 16697211)
1. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
2. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
3. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
6. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
Maione P; Rossi A; Di Maio M; Gridelli C
Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
[TBL] [Abstract][Full Text] [Related]
7. [Recent issues in the treatment of advanced non-small-cell lung cancer].
Negoro S
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1671-9. PubMed ID: 9757191
[TBL] [Abstract][Full Text] [Related]
8. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
9. Triplet chemotherapy combinations with new agents: is there a rationale?
Bunn PA
Semin Oncol; 1998 Aug; 25(4 Suppl 9):55-61. PubMed ID: 9728586
[TBL] [Abstract][Full Text] [Related]
10. Anticipated administration of GM-CSF in the treatment of non small cell lung cancer.
Erkisi M; Erkurt E; Zeren H; Tunali C; Kocabas A; Burgut R
J Exp Clin Cancer Res; 2001 Sep; 20(3):345-9. PubMed ID: 11718213
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
[TBL] [Abstract][Full Text] [Related]
13. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
[TBL] [Abstract][Full Text] [Related]
14. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
Rajan SS; Lyman GH; Stearns SC; Carpenter WR
Med Care; 2011 Jul; 49(7):649-57. PubMed ID: 21478779
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy outcomes in advanced non-small-cell lung carcinoma.
Liu RJ
Semin Oncol; 1993 Aug; 20(4):296-301. PubMed ID: 8393589
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
17. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract][Full Text] [Related]
18. Future directions in the treatment of non-small cell lung cancer.
Shepherd FA
Semin Oncol; 1994 Jun; 21(3 Suppl 4):48-62. PubMed ID: 8209277
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
